Validation of the Spanish Version of the Food Allergy Quality of Life Questionnaire–adult form (S-FAQLQ-AF)

Introducción: Se evalúa el impacto de la alergia alimentaria sobre la calidad de vida, mediante cuestionarios específicos integrado en el proyecto EuroPrevall. Validar y adaptar a lengua castellana el cuestionario FAQLQ-AF. Material y métodos: La traducción y adaptación cultural del cuestionario original se realizó siguiendo recomendaciones de la OMS. Los autores del cuestionario original aceptaron la versión en lengua castellana del FAQLQ-AF (S-FAQLQ-AF). Los pacientes fueron incluidos siguiendo los siguientes criterios: (1) Síntomas alérgicos tras ingesta de un alimento y prick test positivos o IgE frente al alimento implicado, (2) Un médico evaluó la capacidad de los pacientes para completar los cuestionarios (S-FAQLQ-AF y el genérico SF-12). Para explorar la fiabilidad de las respuestas entre 10 y 14 días después de rellenar el primer cuestionario, los pacientes rellenaban de nuevo el S-FAQLQ-AF con preguntas en distinto orden. Resultados: Ochenta y dos pacientes (≥18 años) fueron incluidos. La validez de constructo fue evaluada a partir de la correlación entre el S-FAQLQ-AF y el FAIM (Medida Independiente de la Alergia a Alimentos (rho =0.83, p<.0001). El cuestionario S-FAQLQ-AF (Cronbach-alpha =0.95) y sus diferentes dominios mostraron excelente consistencia interna: Evitación de alérgenos (alpha=0.93); impacto emocional (alpha=0.83), riesgo de exposición accidental (alpha=0.85) y salud relacionada con alergia alimentaria (alpha=0.66). No se halló correlación entre el S-FAQLQ-AF y el cuestionario SF-12. Conclusión: La versión Española del cuestionario de adultos FAQLQ-AF es una herramienta válida, fiable, fácil de usar, rápida de completar y sensible al cambio, discriminando pacientes con diferentes fenotipos atópicos, para evaluar el impacto de la alergia alimentaria en la calidad de vida (AU)

Introduction: Specific food allergy quality of life questionnaires have been developed within the context of the EuroPrevall project. We aimed to adapt and validate the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) in the Spanish language. Methods: The original English questionnaire was translated and culturally adapted into Spanish following World Health Organization guidelines. The final Spanish version of the FAQLQ-AF (S-FAQLQ-AF) was approved by the original authors. Consecutive patients (≥18 years old) who fulfilled the following criteria were recruited: 1) diagnosis of food allergy defined as immediate allergic symptoms and a positive prick test or IgE against the culprit food(s) and 2) physician-assessed ability to complete the questionnaires. Patients completed the S-FAQLQ-AF and a Spanish version of the SF-12 questionnaire. Reliability was assessed 10 to 14 days after completion of the first questionnaire. Results: Eighty-two consecutive outpatients were recruited and cross-sectional validity was assessed based on the correlation between the S-FAQLQ-AF and the Food Allergy Independent Measure (FAIM) in this population (rho=0.83, P<.0001). The S-FAQLQ-AF showed excellent internal consistency (Cronbach alpha, 0.95). S-FAQLQ-AF domains also had excellent internal consistency: alpha=0.93 for allergen avoidance-dietary restrictions; alpha=0.83 for emotional impact; alpha=0.85 for risk of accidental exposure, and alpha=0.66 for food allergy related health. Limited correlation was found between the S-FAQLQ-AF and the SF-12. Conclusion: The S-FAQLQ-AF is a valid, short, easy-to-use, and reliable instrument that discriminates between patients with different atopic phenotypes and is suitable for assessing the impact of IgE-mediated food allergy on patient quality of life (AU)

Urticaria recidivante y tiroiditis autoinmunitaria: influencia del tratamiento con tiroxina en la evolución de la urticaria / Recurrent urticaria and autoimmune thyroiditis: The influence of thyroxine treatment on the outcome of the urticaria

No disponible

Safety of measles-mumps-rubella vaccine (MMR) in patients allergic to eggs.

INTRODUCTION: Since the measles and mumps components used in MMR vaccine are grown in cultures of fibroblast from chick embryos, for a long time there have been concerns about the presence of egg protein in the vaccine and the recommendations given to egg allergic patients. We include in this paper our clinical experience vaccinating egg allergic patients with a regular triple viral vaccine, as well as an immunological study of each vaccine available in Spain. The aim of this study was to evaluate the clinical safety of a conventional MMR vaccine in a population of egg allergic patients and to determine the presence of egg allergens in a conventional MMR vaccine and if IgE antibodies from egg allergic can recognize egg allergens in this vaccine. MATERIALS AND METHODS: Children 15 months old with a confirmed diagnosed of egg allergy were included. In all patients, a skin prick test with non diluted MMR vaccine (Priorix, GSK) was made. If negative, each patient received a single dose of measles, mumps, rubella (MMR) vaccine. If positive, a fractionated injection of the vaccine was made following SEICAP recommendations (2004). SDS-PAGE immunoblotting was performed with Priorix vaccine. RESULTS: A cumulative total of 26 patients with egg allergy have safely received MMR vaccine in a single-dose (after a negative SPT in all cases) at our department without any reaction. 5 sera of vaccinated patients and 6 control sera of egg allergic patients (positive oral challenge) were used to immunolabel the membranes. No positive bands corresponding to egg proteins were found in any of the patients. CONCLUSION: Negative results found in SPT support the absence of clinical reaction against the components and Immunological studies point that there is no detectable amount of egg protein in this vaccine to produce an IgE mediated reaction. We can conclude that MMR can be safely administrated in children allergic to egg.

Safety of measles-mumps-rubella vaccine (MMR) in patients allergic to eggs / Seguridad de la vacuna anti-sarampion-parotiditis-rubeola en pacientes alergicos al huevo

Introduction: Since the measles and mumps components used in MMR vaccine are grown in cultures of fibroblast from chick embryos, for a long time there have been concerns about the presence of egg protein in the vaccine and the recommendations given to egg allergic patients. We include in this paper our clinical experience vaccinating egg allergic patients with a regular triple viral vaccine, as well as an immunological study of each vaccine available in Spain. The aim of this study was to evaluate the clinical safety of a conventional MMR vaccine in a population of egg allergic patients and to determine the presence of egg allergens in a conventional MMR vaccine and if IgE antibodies from egg allergic can recognize egg allergens in this vaccine Materials and methods: Children 15 months old with a confirmed diagnosed of egg allergy were included. In all patients, a skin prick test with non diluted MMR vaccine (Priorix, GSK) was made. If negative, each patient received a single dose of measles, mumps, rubella (MMR) vaccine. If positive, a fractionated injection of the vaccine was made following SEICAP recommendations (2004). SDS-PAGE immunoblotting was performed with Priorix vaccine. Results: A cumulative total of 26 patients with egg allergy have safely received MMR vaccine in a single-dose (after a negative SPT in all cases) at our department without any reaction. 5 sera of vaccinated patients and 6 control sera of egg allergic patients (positive oral challenge) were used to immunolabel the membranes. No positive bands corresponding to egg proteins were found in any of the patients. Conclusion: Negative results found in SPT support the absence of clinical reaction against the components and Immunological studies point that there is no detectable amount of egg protein in this vaccine to produce an IgE mediated reaction. We can conclude that MMR can be safely administrated in children allergic to egg

INTRODUCCIÓN. La vacuna triple vírica (sarampión, parotiditis y rubéola), incluida en el calendario vacunal español, se cultiva en embrión de pollo y esto ha creado controversia durante años acerca del posible presencia de proteínas de huevo y por lo tanto el riesgo de vacunar a niños alérgicos a este alimento. Incluimos en este artículo nuestra experiencia vacunando a niños alérgicos al huevo con la vacuna triple vírica convencional y un estudio inmunológico con las vacunas comercializadas en España. OBJETIVO. Evaluar la seguridad clínica de la vacuna triple vírica comercializada en España en pacientes alérgicos a proteínas de huevo. Evaluar el reconocimiento inmunológico de posibles alergenos de huevo presentes en esta vacuna por pacientes alérgicos a huevo. MATERIAL Y MÉTODOS. Se incluyeron en el estudio niños de 15 meses con diagnóstico confirmado de alergia a proteínas de huevo. En todos los casos se realizó prueba cutánea con la vacuna sin diluir (Priorix, GSK). En caso de que la prueba cutánea fuese negativa se administró la vacuna en dosis única. En caso de positividad de la prueba cutánea, la vacuna se administró de forma fraccionada. Se realizó SDS-PAGE inmunoblot con la vacuna. RESULTADOS. 26 pacientes alérgicos al huevo fueron vacunados con la vacuna triple vírica convencional sin presentar ninguna reacción. Se utilizaron sueros de 5 niños alérgicos vacunados y 6 de niños alérgicos no vacunados en el estudio inmunológico. Ninguno de ellos reconoció ninguna banda correspondiente a proteínas de huevo. CONCLUSIÓN. Los resultados negativos demuestran la ausencia de reactividad clínica frente a los componentes de la vacuna y el estudio inmunológico indica que no hay cantidades detectables de proteínas de huevo en esta vacuna para inducir una respuesta alérgica IgE mediada. Concluimos que la vacuna triple vírica se puede administrar de forma segura en niños alérgicos al huevo